Kyverna Deprioritizes Rapid Manufactured KYV-102

Company Kyverna Therapeutics Event Type Program deprioritization Modality Autologous CD19 CAR T (rapid whole-blood manufacturing) Asset KYV-102 Target CD19 Disease Area Autoimmune disease Summary In the same November 12 disclosure, Kyverna said it elected to deprioritize KYV-102, its rapid whole-blood manufacturing follow-on CAR-T program. The…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *